Komori
Treasury shares4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Status of Share Repurchases

From 18 May to 31 May 2026, 持田製薬 acquired 35,300 treasury shares through market purchases for approximately ¥124 million. The cumulative acquisition based on the resolution of 30 March was also 35,300 shares for the same amount, indicating that the company has just begun utilizing the acquisition limit.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
124315000
¥
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Market purchases on the Tokyo Stock Exchange

Resolved 30 March 2026 / Acquisition period 18 May 2026–18 December 2026

6.7%
Cumulative utilization rate
Limit494,700 株 remaining
Number of Shares530,000 shares (maximum)
6.2%
Cumulative utilization rate
Limit1,875,685,000 円 remaining
Amount¥2,000,000,000 (maximum)

今回の取得が、そのまま決議後の累計です。 株数と金額は、ほぼ同じ速さで消化されています。

Number of Shares
Limit530,000 shares (maximum)
Cumulative total35,300 shares (as of 31 May 2026)
Current35,300 shares
Amount
Limit¥2,000,000,000 (maximum)
Cumulative total¥124,315,000 (as of 31 May 2026)
Current¥124,315,000
Percentage of total issued shares1.50% (percentage of issued shares excluding treasury shares)
Average acquisition price for this transaction (calculated)¥3,522 per shareCurrent acquisition price ÷ current number of shares acquired

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction35,300 shares
Total current acquisition price¥124,315,000
Acquisition date/acquisition period18 May 2026–31 May 2026 (based on contract dates)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Cumulative number of shares acquired35,300 shares (as of 31 May 2026)
Cumulative acquisition cost¥124,315,000 (as of 31 May 2026)
Resolution date30 March 2026
Maximum number of shares to be acquired530,000 shares (maximum)
Total acquisition price¥2,000,000,000 (maximum)
Acquisition period under the resolution18 May 2026–18 December 2026
Percentage of total issued shares1.50% (percentage of issued shares excluding treasury shares)
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the status of the acquisition of treasury shares under the Companies Act. No reason for the acquisition itself is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Repurchases | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori